AI Summary
→ WHAT IT COVERS Biotech Hangout Episode 177 covers the week of March 27, 2026, examining roughly $10 billion in M&A activity including Gilead's $2.2 billion Ouro acquisition and Merck's $6 billion Tern deal, alongside FDA regulatory shifts post-Vinay Prasad, and clinical data from Beam, Sarepta, and Maze Therapeutics. → KEY INSIGHTS - **Biotech relative performance:** XBI is up approximately 2% year-to-date while the S&P 500 is down 6%, an 8-percentage-point spread in three months. Investors tracking sector rotation should note biotech outperforms on up days by roughly 4x the S&P and declines less on down days, suggesting sustained institutional appetite despite macro uncertainty. - **FDA approval pace shift:** Following Vinay Prasad's departure from CBER, the FDA approved three drugs in one week — Denali's Avolaya for Hunter Syndrome, Rocket's gene therapy for LAD-1, and Imvax's Lofurli — several ahead of PDUFA dates. Companies with orphan or rare disease applications should consider filing now while regulatory flexibility appears elevated under commissioner pressure. - **Oral psoriasis market expansion:** J&J's icicotide approval plus upcoming AAD data from Alumis and Takeda signal the first genuinely efficacious oral psoriasis therapies. Dermatology investors should model market expansion from $20–30 billion toward $40+ billion as millions of patients currently using only topicals gain access to convenient, biologic-comparable oral options. - **Tern/Merck acquisition premium warning:** Merck acquired Tern Pharmaceuticals — developer of TRN-701, a best-in-class CML drug comparable to Novartis' Scemblix — at only a 6% premium to market price. Biotech boards and investors should scrutinize low-premium acquisitions carefully, as selling at market price eliminates future optionality that existing shareholders may have already priced in. - **APOL1 kidney disease market sizing risk:** Maze Therapeutics' MZ-829 data showed strong UPCR reductions in FSGS patients with two APOL1 alleles but minimal effect in diabetic APOL1 patients, sending the stock down 40%. Investors in Vertex's enaxaplan Phase 3 program should reassess addressable market assumptions — the opportunity may be closer to FSGS-only patients than the 250,000-patient APOL1-broad estimate. → NOTABLE MOMENT A single patient in Beam Therapeutics' AATD base-editing trial developed an infection post-treatment — typically dangerous for this condition — yet the corrected gene automatically upregulated healthy protein production in response, demonstrating that the therapy restored natural biological stress response rather than simply supplementing a missing protein. 💼 SPONSORS None detected 🏷️ Biotech M&A, FDA Regulation, Gene Editing, Psoriasis Therapeutics, APOL1 Kidney Disease